Therapeutic agent for inflammatory bowel disease and tnf-alpha production inhibitor

Abstract

Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

1 . An agent for treatment or prevention of an inflammatory bowel disease wherein it contains one or more amino acids selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, and the amino acids are administered in an amount of 0.1 to 4000 mg/kg per day. 
     
     
         2 . The agent for treatment or prevention of the inflammatory bowel disease of  claim 1  wherein it contains one or more amino acids selected from the group consisting of lysine, histidine, phenylalanine, tryptophan and glutamine. 
     
     
         3 . The agent for treatment or prevention of the inflammatory bowel disease of  claim 1  wherein it contains tryptophan. 
     
     
         4 . The agent for treatment or prevention of the inflammatory bowel disease of  claim 3  wherein it further contains one or more amino acids selected from the group consisting of lysine, histidine, phenylalanine and glutamine. 
     
     
         5 . An agent for treatment or prevention of an inflammatory bowel disease wherein it contains 0.5 to 2% by weight of tryptophan, 3 to 9% by weight of lysine, 1.5 to 5% by weight of histidine, 4 to 10% by weight of phenylalanine and 9 to 23% by weight of glutamine, and the amino acids are administered in an amount of 0.1 to 4000 mg/kg per day. 
     
     
         6 . The agent for treatment or prevention of the inflammatory bowel disease of  claim 1 , wherein the inflammatory bowel disease is Crohn's disease. 
     
     
         7 . The agent for treatment or prevention of the inflammatory bowel disease of  claim 1 , wherein the inflammatory bowel disease is ulcerative colitis. 
     
     
         8 . An inhibitor of TNF-α production wherein it contains amino acids selected from the group consisting of histidine, phenylalanine and tryptophan, and the amino acids are administered in an amount of 0.1 to 4000 mg/kg per day. 
     
     
         9 . An inhibitor of TNF-α production wherein it contains 0.5 to 2% by weight of tryptophan, 3 to 9% by weight of lysine, 1.5 to 5% by weight of histidine, 4 to 10% by weight of phenylalanine and 9 to 23% by weight of glutamine, and the amino acids are administered in an amount of 0.1 to 4000 mg/kg per day.